Jazz Pharmaceuticals JAZZ Total Neuroscience — Total revenues

Other product segments

Similar metrics at other companies

PENNeuro — Revenue

$171.41M+38.9%

NBIXNet product sales — Total revenues

$811M+43.9%

INCYNet sales — Total revenues

$1.1B+19.8%

NBIXReportable Segment — Total revenues

$814.5M+42.2%

JNJOTHER NEUROSCIENCE — Percent Change (as a percent)

-5.4%-2.3pp

MEDPCentral Nervous System — Total Revenue

$56.26M-3.5%

Questions, answered.

What is Jazz Pharmaceuticals's total neuroscience — total revenues?

Jazz Pharmaceuticals (JAZZ) reported total neuroscience — total revenues of $791.86M in Q4 2025.

How has Jazz Pharmaceuticals's total neuroscience — total revenues changed year-over-year?

Jazz Pharmaceuticals's total neuroscience — total revenues increased by 8.4% year-over-year, from $730.47M to $791.86M.

What is the long-term trend for Jazz Pharmaceuticals's total neuroscience — total revenues?

Over 3 years (2022 to 2025), Jazz Pharmaceuticals's total neuroscience — total revenues has grown at a 1.4% compound annual growth rate (CAGR), from $2.76B to $2.88B.

What does total neuroscience — total revenues mean?

The total sales generated by the company's neuroscience division.

How do you interpret total neuroscience — total revenues?

An increase indicates successful market penetration, effective pricing strategies, or growth in patient demand for neurological therapies, while a decrease may signal competitive pressure or patent expirations.

How does total neuroscience — total revenues compare across companies?

Comparable to segment-specific revenue reporting in other biopharmaceutical firms focusing on CNS or specialty therapeutic areas.